Abstract
This cohort study investigates mortality and cause of death among a large cohort of androgenic anabolic steroid users, compared with a control group, in Denmark from January 3, 2006, to March 1, 2018.
Androgenic anabolic steroids (AAS) are highly effective in promoting muscle growth.1,2 In 2014, it was estimated that about 3 million to 4 million individuals in the US had used AAS in their lifetime.1 Unfortunately, these drugs are associated with a range of serious adverse effects including severe cardiovascular and psychiatric morbidity and death.2,3 However, data are limited to case reports and smaller cohorts.2 We investigated mortality and cause of death among a large cohort of AAS users, with a comprehensive follow-up period, and compared the cohort with a control group.
Methods
We included Danish males who received a doping sanction of 2 years of sports exclusion as part of an AAS antidoping program, identified through sporadic inspections and drug testing in fitness centers in Denmark from January 3, 2006, to March 1, 2018.3 These centers were accessible to the public and members were informed about the possibility of unannounced doping controls. The cohort encompassed both casual and dedicated gym visitors. For each AAS user, 50 male control participants from the general population were randomly included through the Danish Civil Registration System.4 Control participants were matched by age and enrollment day. Follow-up continued until death, migration, or June 30, 2023.
Every resident in Denmark is assigned a personal identification number used for interactions with the health care system.4 We cross-referenced the personal identification numbers of study participants with the Danish Civil Registration System to obtain records on their living status and, for those deceased, their exact dates of death. Additionally, we identified the primary causes of death, as determined by physicians, from the National Causes of Death Register.4 These were categorized into natural or unnatural causes (accidents, violent crimes, or suicide). To ensure anonymity, a complete list of death causes was not permitted.
All-cause mortality was investigated with the Kaplan-Meier estimator, and statistical significance was assessed with the log-rank test. Hazard ratios (HRs) were estimated with Cox proportional hazard regression models. Causes of death were analyzed with a competing risk model, incorporating unknown death causes through imputation based on complete cases (Supplement 1). Statistical significance was determined at a 2-sided P < .05. HRs were presented with 95% CIs. All statistics were computed in SAS version 9.4 (SAS Institute Inc).
This register-based study, not requiring informed consent according to Danish law, received approval from the Danish National Board of Health and the Danish Data Protection Agency.
Results
This study included 1189 males sanctioned for doping with AAS and 59 450 male control participants. The mean age among AAS users and control participants was 27.4 (SD, 6.9) years.
The cohort had a mean follow-up time of 11 years (Table). In the control cohort 5.47% were right censored due to migration, compared with 2.10% for AAS users.
Table. Cohort Characteristics and Study Outcomes.
| AAS users (n = 1189) | Control participants (n = 59 450) | |
|---|---|---|
| Age at baseline, mean (SD), y | 27.4 (6.9) | 27.4 (6.9) |
| Duration of follow-up, mean (SD), y | 11.2 (3.4) | 11.0 (3.6) |
| Follow-up time, person-y | 13 305 | 654 938 |
| Death, No. | 33 | 578 |
| Cause of death, No. | ||
| Unnatural | 17 | 208 |
| Natural | 16 | 334 |
| Unknown | 0 | 36 |
Abbreviation: AAS, androgenic anabolic steroids.
During follow-up 33 AAS users died, compared with 578 in the control group, resulting in an HR of 2.81 (95% CI, 1.98-3.99; P < .001) (Table and Figure). Among AAS users, there were 17 deaths categorized as unnatural, primarily from accidents, and 16 deaths classified as natural causes, with the most prevalent causes being cancer and cardiovascular disease. Among the control participants, there were 334 natural deaths—208 unnatural, and 36 with unknown causes. The HR for an unnatural death among AAS users compared with control participants was 3.64 (95% CI, 2.22-5.96; P < .001); for natural death, the HR was 2.24 (95% CI, 1.36-3.70; P = .002).
Figure. Time to Death for Users of Androgenic Anabolic Steroids and Control Participants.
Mortality was statistically significantly higher among androgenic anabolic steroid (AAS) users by log-rank test (P < .001).
Discussion
This study found an increase in mortality from both natural and unnatural causes among AAS users sanctioned in fitness centers compared with control participants. The increased risk of death among AAS users aligns with results from smaller cohort studies.2
Study limitations include its observational nature, which does not establish causality, and an absence of adjustment for potential confounding variables affecting health. In Denmark, AAS use is considered outside social norms.3,5 Behaviors possibly associated with AAS use, such as risk-taking propensities or the use of other substances, may contribute to the elevated mortality risks observed.1,5
Section Editors: Kristin Walter, MD, and Jody W. Zylke, MD, Deputy Editors; Karen Lasser, MD, Senior Editor.
eMethods
eReferences
Data Sharing Statement
References
- 1.Pope HG Jr, Wood RI, Rogol A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375. doi: 10.1210/er.2013-1058 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Smoliga JM, Wilber ZT, Robinson BT. Premature death in bodybuilders: what do we know? Sports Med. 2023;53(5):933-948. doi: 10.1007/s40279-022-01801-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333-340. doi: 10.1111/joim.12850 [DOI] [PubMed] [Google Scholar]
- 4.Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563-591. doi: 10.2147/CLEP.S179083 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Christiansen AV, Vinther AS, Liokaftos D. Outline of a typology of men’s use of anabolic androgenic steroids in fitness and strength training environments. Drugs Educ Prev Policy. 2017;24(3):295-305. doi: 10.1080/09687637.2016.1231173 [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
eMethods
eReferences
Data Sharing Statement
